WASHINGTON (Reuters) -Robert F. Kennedy Jr., President Donald Trump's pick to lead the top U.S. health agency, came under attack at a Senate confirmation hearing on Wednesday, with Democratic ...

A clinical trial has found that Novavax’ COVID-19 vaccine is 86% protective against the UK variant of SARS-CoV-2, only slightly lower than the 96% efficacy seen with the original strain of the ...

A freshman Idaho lawmaker wants to ban most COVID-19 shots for the next decade, with a bill rooted in misconceptions about ...

With the triad of respiratory viruses present in our day-to-day, it is recommended that individuals receive both COVID-19, flu, and occasionally RSV and MPox vaccinations. However, there is a common ...

Novavax takes the RNA sequence that codes and ... even the product features themselves: efficacy, longer duration and durability, and safety profile.” The press conference in Sweden might ...

It expects to receive the safety and efficacy data on Chinese firm Sinovac ... vaccine doses from China's Sinovac, Maryland-based Novavax and Covax, an international Covid-19 vaccine allocation ...

According to Jefferies analyst Michael Yee, COVID vaccinations involving Moderna, Pfizer and Novavax products dropped by 8% at the ... Foroohar wrote in a Leerink note to clients Monday. Final ...

Robert F. Kennedy Jr., President Donald Trump’s controversial pick to lead the U.S. Department of Health and Human Service , came under attack at a Senate confirmation hearing on Wednesday, with ...

A significant catalyst is the anticipated data release from the Phase 2 LunairCF study in the first half of 2025, which focuses on the efficacy and safety of ARCT-032 for cystic fibrosis treatment.

I have been warning about Novavax's risks since 2016, highlighting its ongoing struggles with the FDA. Novavax's Q3 2024 earnings call and 10-Q reveal a collaboration negotiated from a position of ...